Xspray Pharma AB (publ)

Stockholm Stock Exchange XSPRAY.ST

Xspray Pharma AB (publ) Price to Book Ratio (P/B) on January 14, 2025: 1.54

Xspray Pharma AB (publ) Price to Book Ratio (P/B) is 1.54 on January 14, 2025, a -5.85% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Xspray Pharma AB (publ) 52-week high Price to Book Ratio (P/B) is 4.14 on June 12, 2024, which is 169.14% above the current Price to Book Ratio (P/B).
Xspray Pharma AB (publ) 52-week low Price to Book Ratio (P/B) is 1.41 on January 10, 2025, which is -8.43% below the current Price to Book Ratio (P/B).
Xspray Pharma AB (publ) average Price to Book Ratio (P/B) for the last 52 weeks is 2.44.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Stockholm Stock Exchange: XSPRAY.ST

Xspray Pharma AB (publ)

CEO	Dr. Per Andersson Ph.D.
IPO Date	Sept. 28, 2017
Location	Sweden
Headquarters	Råsundavägen 12
Employees	24
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.

Key trends

Past 5 years